Siegfried Holding AG
0QQO.L
London Stock Exchange74.45
CHF
+0.45
- -
Siegfried Holding AG
0QQO.L
(London Stock Exchange)
Recent
price
74.45
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Siegfried Holding AG is a Switzerland-based contract development and manufacturing organization (CDMO) that develops and produces active pharmaceutical ingredients (APIs), intermediates and finished dosage forms for the pharmaceutical industry; its Drug Substances offerings include exclusive synthesis of custom APIs, a broad portfolio of non-exclusive APIs focused on anesthetics, analgesics, decongestants and addiction treatments, as well as intermediates and controlled substances; Drug Products encompass oral solid dosage forms such as tablets and capsules, sterile and aseptic filling in vials, ampoules, cartridges and pre-filled syringes, ophthalmics including sterile ointments, gels, suspensions and solutions, inhalation products in medical device capsules, and viral vectors for gene therapy through subsidiary DINAMIQS. The company operates 13 production sites across seven countries in Europe, North America and Asia, including headquarters in Zofingen, Switzerland, with key facilities in the US (Pennsville, Irvine, Grafton), Germany (Hameln, Minden), Spain (Barberà del Vallès, El Masnou), Malta, China (Nantong) and France (St. Vulbas). Founded in 1873, Siegfried serves over 500 customers worldwide across generic and innovative drug sectors, supplying approximately 200 FDA-approved APIs and supporting up to one billion patient contacts annually. In July 2024, Siegfried acquired a US-based early-phase CDMO in Grafton, Wisconsin, strengthening its Drug Substances capabilities and North American presence; the company launched its updated EVOLVE+ strategy in October 2024, emphasizing commercial, development and operational excellence alongside value-accretive M&A; recent investments include a new quality control lab in Minden (August 2024), cutting-edge viral vector labs for DINAMIQS in Zurich (November 2024) and a global R&D center for Drug Substances in Evionnaz (November 2024).